Clinical Trial: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07473752) titled 'A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects' on March 10.

Brief Summary: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

Study Start Date: July 18, 2023

Study Type: INTERVENTIONAL

Condition: Phase 1 First-in-human Study Involving Healthy Subjects

Intervention: DRUG: TNX-1500

The active ingredient is an anti-CD154...